Cargando…

Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?

Transplants have been used to treat chronic lymphocytic leukemia (CLL) for more than 35 years. Use has been restricted to <1 percent of highly selected persons typically failing concurrent conventional therapies. As therapies of CLL have evolved, so have indications for transplantation and transp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shenmiao, Huang, Xiaojun, Gale, Robert Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201027/ https://www.ncbi.nlm.nih.gov/pubmed/34200119 http://dx.doi.org/10.3390/jcm10112516

Ejemplares similares

Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia
por: Fatima, Narjis, et al.
Publicado: (2020)

Validation of the Chinese EORTC chronic lymphocytic leukaemia module – application of classical test theory and item response theory
por: Dong, Dong, et al.
Publicado: (2020)

Chronic Lymphocytic Leukaemia—New Drugs and Management: CME Lecture
por: Hamblin, Terry J
Publicado: (1995)

Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia
por: Hartman, Mariusz L., et al.
Publicado: (2013)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies
por: Khan, Sujoy, et al.
Publicado: (2023)

Prospects for achieving treatment‐free remission in chronic myeloid leukaemia
por: Saglio, Giuseppe, et al.
Publicado: (2020)

Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
por: Prochazka, Katharina T., et al.
Publicado: (2021)

Perspectives on the Application of Cytogenomic Approaches in Chronic Lymphocytic Leukaemia
por: Wan Mohamad Zamri, Wan Norizzati, et al.
Publicado: (2023)

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
por: Alikian, Mary, et al.
Publicado: (2017)

Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma
por: Yang, Shenmiao, et al.
Publicado: (2020)

miRNAs in Lymphocytic Leukaemias—The miRror of Drug Resistance
por: Sbirkov, Yordan, et al.
Publicado: (2022)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?
por: Dreger, P., et al.
Publicado: (1998)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

A case of leukaemia cutis in a dog with T‐cell chronic lymphocytic leukaemia
por: Bae, Hyeona, et al.
Publicado: (2022)

UGT2B17 modifies drug response in chronic lymphocytic leukaemia
por: Allain, Eric P., et al.
Publicado: (2020)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Ribosomal RNA Synthesis in Chronic Lymphocytic Leukaemia
por: Billington, R. W., et al.
Publicado: (1974)

Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation
por: Sander, Birgitta, et al.
Publicado: (2022)

Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia
por: Koehler, Philipp, et al.
Publicado: (2012)

The Uptake and Utilization of Chlorambucil by Lymphocytes from Patients with Chronic Lymphocytic Leukaemia
por: Hill, Bridget T., et al.
Publicado: (1972)

Chronic lymphocytic leukemia in China
por: Gale, Robert Peter
Publicado: (2022)

Comment on: “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Papamichos, Spyros I., et al.
Publicado: (2020)

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
por: Holmes, Katie B., et al.
Publicado: (2019)

Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy
por: Sun, Wei, et al.
Publicado: (2022)

Colonic Involvement in a Patient with Chronic Lymphocytic Leukaemia
por: Arkkila, P. E. T., et al.
Publicado: (2008)

Chronic lymphocytic leukaemia during pregnancy: management and thoughts
por: Winckler, Patricia, et al.
Publicado: (2015)

The clinical implications of gene mutations in chronic lymphocytic leukaemia
por: Rossi, Davide, et al.
Publicado: (2016)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia
por: Li, Xingjian, et al.
Publicado: (2019)

COVID-19 in a patient with chronic lymphocytic leukaemia
por: Jin, Xiang-Hong, et al.
Publicado: (2020)

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived
por: Milne, Kate, et al.
Publicado: (2020)

Whipple’s Disease as the First Manifestation of Chronic Lymphocytic Leukaemia
por: Guiomar, Verónica, et al.
Publicado: (2019)

An Unusual Case of Chronic Lymphocytic Leukaemia Involving the Cervix
por: Hamer, Jack, et al.
Publicado: (2022)

Expert consensus on the management of chronic lymphocytic leukaemia in Asia
por: Tse, Eric, et al.
Publicado: (2023)

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
por: Smolej, Lukáš, et al.
Publicado: (2021)

Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro
por: Amrein, Lilian, et al.
Publicado: (2009)

Studies of the Dissemination and Quantitative Transplantation of a Lymphocytic Leukaemia of CBA Mice
por: Hewitt, H. B.
Publicado: (1958)

PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target
por: Sbrana, Francesca Vittoria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cl71nbenjfcm9esvg3voofb8c9